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A short review is given of the pharmokinetics and
pharmacodynamics of the decarboxylase inhibitor Ro 4-
4602. The results obtained in 20 patients using this drug
in combination with L-dopa, (Madopar), are described.
Reduction in the total dosage of L-dopa by one-sixth
to one-tenth the single preparation gave marked relief of
nausea.
The induction period of the dosage was smoother, and
an optimum dose could be reached sooner with earlier
signs of improvement in comparison with the single drug.
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occurs in the gastro-intestinal tract.' This is of the- greatest
importance because dopamine itself (Fig. 1) does not
cross the blood-brain barrier, and the extent to which dopa
is converted determines the quantity of dopa available for
penetration into the brain. In man, absorption from the







DOPA-decarboxylase (? iso- enzyme of
L-arornaric alnino-acir 1ecarboxylase).
Fig, 1. Metabolic pathway involving dopa.
There are several substances with decarboxylase-inhibi-
ting properties. These 5.ubstances were developed more than
a decade ago for the treatment of arterial hypertension, but
it soon became clear that the decarboxylation of d.opa
was not a limiting step in the formation of catecholamines.
In 1966 Udenfriend et al." noted that a decarboxylase
inhibitor (MK-485) actually decreased the dopa-induced
increase of catecholarnines in the .brain in vivo. The
following year the added beneficial effect of another
decarboxylase inhibitor, bensarazid Ro 4-4602, to L-dopa
in the treatment of Parkinson's disease, was described by
Birkmayer and Mentasti.6
Ro 4-4602 is an amino-acid hydrazine derivative (N-
(DL-seryI)-N'(2,3,4, trihydroxybenzyl)-hydrazine (HCI)
(Fig. 2). In 1967 Bartholini et al.' demonstrated experi-
mentally that the effect of Ro 4-4602 is due to preferential
inhibition on extracerebral· decarboxylase. This increased
L-dopa (L-3,4-dihydroxyphenylalanille), an aromatic ami-
no acid, although the present drug of choice in the
treatment of patients with Parkinson's disease, is not an
easy drug for use by inexpert hands. During the induction
phase of treatment, its dosage has to be increased slowly,
clinically titrated against the enzyme systems responsible
for its degradation, adjusted to the patient's individual
tolerance; and the maintenance phase is complicated by
the appearance of side-effects.
In 30 patients treated with this drug, the author'"
encountered the same number of treatment failures and
side-effects such as nausea and vomiting, postural hypo-
tension, dyskinesias and psychic changes as described in
other larger series. We have not seen cardiac arrhythmias as
a complication." Long-term treatment has shown that
diurnal intermittent episodes of bradykinesia, so-called
akinesia paradoxica' or the on-off phenomenon," appear.
It has been suggested that this may be related to the
amount of protein in the diet." An increase in serum
growth hormone levels has been established, probably
correcting a basic defective output of growth hormone in
the disease itself," but carrying a risk of iatrogenic
acromegaly."
This has led to the search for other substances which
could modify the response of L-dopa, particularly those
by which the total dose of L-dopa could be reduced.
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Fig. 2. Stnlctural formula of bensarazid.
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the titrated dopa in the blood, and consequently appeared
to increase the supply of the brain with the amino acid.
Exogenous dopa is decarboxylated and further metabo-
lised within the cerebral capillary walls as shown by
histofluorometric methods;" the accumulated dopamine
produces a green fluorescence of these structures. ~his
dopa-induced green fluorescence disappears In the capIlla-
ries, and is enhanced in the brain parenchyma when Ro 4-
4602 is given; indicating that Ro 4-4602 inhibits the
decarboxylase within the capillary walls, thereby protecting
the dopa from being metabolised before entering the
brain parenchyma."
Experimentally Ro 4-4602 causes skeletal alterations in
orowing rats. This is of no clinical significance in patient~
~ith Parkinson's disease who have passed this develop-
mental stage many years previously. In dogs, mass loss
in combination with diarrhoea, fatty degeneration of the
liver with impaired hepatic function (with protracted pro-
thrombin time according to the Quick technique) and
cytostatic effects on the bone marrow were noted.
Terminal increase in serum urea was attributed to liver
damage, as no changes in the kidneys could be detected.'9
Clinical trials have demonstrated the effectiveness of
Madopary,H Apart from gastric bleeding in patients who
all had a previous history of peptic ulceration," no toxic
effects have been observed. However, all patients with
such a history, patients suffering from systemic bone
disease, patients with severe liver damage, and all female
patients of child-bearing age, have been excluded from
trials.
The main problem has been to establish the optimum
ratio between dopa and Ro 4-4602. According to BarbeaulO
the safest clinical results (i.e. satisfactory improvement
with minimal neurological side-effects) are obtained with
and L-dopa: Ro 4-4602 ratio between 3 : I and 3 : 2, with a
maximum of 400 mg daily of the decarboxylase inhibitor.
Their previously recommended 4 : 1 ratio' gives optimal
clinical effects on neurological signs, almost always causes
severe hypotonia, and carries the risk of fairly abnormal
involuntary movements.*
PATIENTS AND METHODS
In our trial the drugs supplied contained the ratios of L-
dopa and Ro 4-4602 in the reverse sequence. From January
1972 until September 1972 the 3:2 combination was used:
from September 1972 onwards the 4 : 1 ratio. The trial is
thus divided into two sections.
Twelve patients were included in the trial on the 3:2
ratio of drugs. There were 6 men (aged 44 - 75 years) and
6 women (aged 55 - 70 years). The mean duration of their
illness was 7-} years (ranging from 3 to 14 years). Ten were
on L-dopa when treatment was started and their dosages
varied from 2,5 g to 6 g per day. Their clinical disability
was graded according to the stages of Hoehn and Yahr:
3 were in stage Il; 5 in stage Ill; 4 were in stage IV.
Changing over from L-dopa to Madopar caused no change
in the clinical rating of their disability in 8 patients, 3
improved, and only 1 deteriorated. Apart from this
"Since this paper was submitted for publication. Barbeau h~5 reaffirmed
that the ratio best tolerated in practice is 4: 1. (Advances lfl Neurology
vo!. 2, pp. 173 - 198. New York: Raven Press, 1973).
single patient all preferred the combination drug, as this
reduced the incidence of nausea very considerably. No
change was noted in the occurrence of postural hypotension.
One patient died during this period (female, aged 70 years,
14 years' duration of disease and clinically stage IV), from
acute basilar artery thrombosis. No autopsy was done.
Tn the second stage of the trial on the 4 : 1 combination
of drugs, 18 patients participated, including 10 patients
from the previous group. These included 7 men (aged 44-
75 years) and 11 women (aged 34 - 71 years). The mean
duration of their illness was 9-} years (ranging from
1-} to 17 years). Of these, 4 were on L-dopa before starting
treatment, 9 on the 3:2 combination and 5 newly-diagnosed
patients. Their clinical disability varied from stage IT
(6 patients), stage III (8 patients) to stage IV (4 patients).
Of the 5 patients starting on treatment for the first time,
2 could not tolerate the drug at all: one became violently
nauseous after a single dose and the other very restless
and agitated, so that in both the drug was immediately
discontinued. The patient mentioned in the first group who
discontinued use of the 3:2 combination, tried this 4: I
combination for 4 months without improvement and
reverted to the L-dopa alone. The other 9 patients who
were changed over from the 3:2 to the 4: 1 combination
showed no change in 6 patients and deterioration in 3.
These 3 showed striking akinesia paradoxica. As it was
felt that this was part of the long-term effect of L-dopa
treatment, it could not be attributed to the combination
of drugs: treatment was therefore not discontinued.
The other 3 'new' patients all improved. Of 3 pa~ients
previously on L-dopa, 2 improved, and 1 showed no
change. Again the most striking benefit obtained was relief
of nausea.
Dosage
Where L-dopa had been used alone before, the dosage was
first reduced by half, or more, until the signs and symptoms
of Parkinson's disease became obvious again. A gradual
substitution was then made with the new drug-combination
until it was felt that the previous clinical state had been
reached. Further dose increments were then made as
required. However, at a later stage, an immediate switch-
over from the single to the combination drug w<\s made
without any noticeable deleterious side-effects. Where a
new patient started treatment the drug-combination was
introduced slowly, with daily increases until a dose level
was reached which was considered effective. In contrast
to the single preparation, the introduction and increases
'in dose of the drug combination were smoother, accompa-
nied by very little nausea, and a quicker response to
treatment was seen. In the single drug this often took
months to achieve. whereas the effect could now be seen
within 1 - 2 weeks.
LABORATORY INVESTIGATIONS
During the first month of each trial laboratory investi-
gation~ were carried out at 14-day intervals, thereafter at
intervals of 6 - 8 weeks. These tests included erythrocyte
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sedimentation rate (ESR), haemoglobin, haematocrit, red
cell count, mean corpuscular volume, mean corpuscular
haemoglobin, mean corpuscular haemoglobin concentration,
total white cell count and differential count, platelet count
and reticulocyte count. Serum chemistry monitored in-
cluded serum enzymes, glutamic pyruvic transaminase
(GPT), glutamic oxaloacetic transaminase (GOT), lactic
acid dehydrogenase (LDH), alkaline phosphatase (AP),
total serum protein, serum albumin, serum globulin, total as
well as fractionated serum bilirubin, uric acid, calcium,
phosphate, urea and cholesterol levels.
Infrequent, scattered, transiently raised values of some
of these enzymes were found from time to time in most
patients, the one most frequently occurring being a raised
serum LDH, which was found 18 times in 11 patients
over a period of 18 months. One patient (male, aged 70
years, duration of illness 6 years, clinically disabled stage
Ill, previously on L-dopa only at 3 g daily for 3 years)
showed transient raised GOT, LDH and bilirubin values,
never simultaneously, and each reverting to normal spon-
taneously without discontinuation of the drug. Only 1
patient showed fairly consistently raised urea values
(female, aged 68 years, duration of disease 5 years, clinical
degree of disablement stage Ill), but as she was a hyper-
tensive of many years' standing, the raised urea was
considered to be due to this condition and not to reflect
a side-effect of the drugs. She also had a consistently
raised ESR.
DISCUSSION
We have compared the amounts of L-dopa required when
this drug is given singly or in combination with Ro 4-4602
(Table I). This comparison was possible in 13 patients;
7 patients had not been on the single preparation before
and were therefore not included. The comparison shows
that whereas the range of dosage of L-dopa on its own
varied widely, from 1,5 g to 6 g, that of the 3:2 and 4:1
combinations varied from 375 mg to 800 mg and 300 mg
TABLE I. COMPARISON OF THE TOTAL DAILY DOSES
REQUIRED OF L-DOPA ONLY AND OF THE L-DOPA CON-
















6 600 - 600
6 450 600
to 800 mg respectively, with a mean of 502 mg and
545 mg respectively.
There is therefore a very significant reduction in over-
all dosage of L-dopa. The narrower variation in dosage
of the two drug combinations is due to the reduction in
dose of L-dopa, correspondingly less nausea and vomiting,
and those patients who could previously not tolerate an
increase in L-dopa now approached dosages similar to
those of patients who had been able to tolerate the higher
doses.
At first sight, the difference in mean dosage of L-dopa
between the two drug combinations appears small, giving
the impression that in the final analysis there is little to
choose between the two combinations. This is not so.
With the 3:2 combination we quite quickly reached the
maximum recommended 400 mg dose of decarboxylase
inhibitor, and only exceeded this in 2 patients for a
period of 6 weeks; in neither case was any added benefit
obtained. With the 4: 1 combination the maximum dose
decarboxylase inhibitor was 200 mg, therefore permitting
greater increase for the future if required. However, this
increase could conceivably be offset by the disadvantageous
effects recorded by Barbeau et al."
The greatest advantage of the drug combination has
been the very greatly reduced incidence of nausea and
vomiting, suggesting that the site of this cause is pre-blood-
brain barrier,"'" and related to the absolute dose of L-
dopa.
There has been no observable effect on blood pressure.
Four patients have shown a steady deterioration through-
out the 18 months of the trial. All were patients with
marked symptoms of Parkinson's disease at the commence-
ment of the trial, and the deterioration is presumably
due to the natural course of the disl:;ase. Four patients
have also shown a marked diurnal fluctuation in motor
ability, mainly an afternoon 'increase in bradykinesia, a
previously recognised long-term effect of L-dopa therapy.
Five patients have shown a decrease in the degree of
involuntary movements, and 3 patients have remained the
same. These involuntary movements are dose- and time-
related, appearing in 50% of patients after 3 months, and
in 80)0 after 2 years." It would appear that the plasma
concentration of L-dopa at which dyskinesias occur is an
individual level for each patient, and' that this level is
the same on the single drug or the combination drug.""
This suggests that attempts to improve therapeutic results
by an absolute increase of the drug at the blood-brain
barrier will be unsuccessful, except where the limiting
factor previously has been severe gastro-intestinal side-
effects.
The administration of L-dopa to experimental animals
produces multiple biochemical changes: One possible
explanation for these involuntary movements is that decar-
boxylated L-dopa is distributed widely in the brain, while
in adrenergic neurones only the enzyme dopamine hydrox-
ylase reacts with dopamine to produce excess norepine-
phrine, which then mediates these movements. As dys-
kineslas are seldom seen in non-Parkinson patients treated
with L-dopa, this suggests a denervation supersensitivity
following extensive striatal degeneration.
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l1adopar (Ro 8-0576) (L-dopa + Ro 4-4602) was generous-
mpplied by Messrs Roche Products.
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Standardisation of the Nitro-blue Tetrazolium
~est and Factors Mfecting its Clinical Application
R. SHER, R. ANDERSON, A. R. RABSON, H. J. KOORNHOF
SUMMARY
,ttempting to standardise the nitro-blue tetrazolium (NBT)
lst, the following modifications of previously described
rocedures were introduced. Leucocyte-rich plasma ob-
lined by simple gravitation at 37°C was mixed with NBT
~agent which had previously been centrifuged to remove
ndissolved particles. Thick smears were made and stained
'ith dilute haematoxylin, and physical manipulation during
le various procedures was reduced to a minimum. Re-
onstitution of the buffy coat in fresh normal serum did
ot alter the NBT result.
Normal NBT readings were obtained in pregnant fe-
tales, and women on contraceptive hormonal preparations.
. Afr. Med. l., 48, 209 (1974).
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The nitro-blue tetrazolium (NBT) test has been shown by
a number of workers to be useful in the diagnosis of
chronic granulomatous disease'" and to monitor the
progress of bacterial infections.' The test has also been
shown to be positive in mycoplasma,' fungal, and protozoal
infections such as malaria, and in various parasitic infesta-
tions."" The qualitative NBT test is now used as a
routine in many hospital laboratories.",·,·,n
Since the original description by Park et al.,'· however.
contradictory reports have appeared in the literature
with regard to the normal NBT test values,"·H the effect
of pregnancy on the results," and the findings in viral
meningo-encephalitis.'" Because of the contradictions and
the problems which were encountered in our laboratories,
such as when neutropenia was present, and differentiating
the formazan particle from heavily stained polymorpho-
nuclear neutrophilic (PMN) nuclei using Romanowsky
stain, the method of Park et al. IQ was critically examined.
It was found necessary to introduce minor modifications
mainly with a view to minimising undue stimulation of
PMN cells during the laboratory procedures. Alterations to
Park et al.'s'· original method were also advocated by
Freeman and King."'" We are in agreement with most of
their modifications. Our study was carried out indepen-
